Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.46 |
| ▸ | GPBAR1 | Q8TDU6 | 12/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30219246 | 1.00 | CES2 (0.46) | CES2GPBAR1MAPTGAALMNA | |
| SCHEMBL9797089 | 0.86 | CES2 (0.48) | CES2MAPTGAALMNAPOLB | |
| SCHEMBL11300330 | 0.85 | GAA (0.44) | CES2GPBAR1MAPTGAALMNA | |
| SCHEMBL13513411 | 0.84 | CES2 (0.47) | CES2GPBAR1AKR1C3 | |
| SCHEMBL12097304 | 0.84 | GPBAR1 (0.47) | CES2GPBAR1MAPTAKR1C3 | |
| SCHEMBL30738524 | 0.84 | GPBAR1 (0.47) | CES2GPBAR1MAPTAKR1C3 | |
| SCHEMBL12097284 | 0.83 | CES2 (0.46) | CES2GPBAR1AKR1C3 | |
| SCHEMBL31443004 | 0.83 | CES2 (0.46) | CES2MAPTGAALMNAPOLB | |
| SCHEMBL28522802 | 0.83 | CES2 (0.46) | CES2MAPTGAALMNAPOLB | |
| SCHEMBL627995 | 0.81 | CES2 (0.67) | CES2MAPTGAALMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9550757-B2 | Nuclear transport modulators and uses thereof | Karyopharm Therapeutics Inc. (US) | 2017-01-24 | — | — | US | disclosed |
| EP-2542089-B1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | KARYOPHARM THERAPEUTICS INC (US) | 2017-01-18 | — | — | EP | disclosed |
| CN-103402359-B | Olefin containing nuclear transport regulator and application thereof | 卡尔约药物治疗公司 | 2016-08-24 | — | — | CN | disclosed |
| US-9303000-B2 | Olefin containing nuclear transport modulators and uses thereof | Karyopharm Therapeutics Inc. (US) | 2016-04-05 | — | — | US | disclosed |
| US-9303000-B2 | Olefin containing nuclear transport modulators and uses thereof | Karyopharm Therapeutics Inc. (US) | 2016-04-05 | — | — | US | disclosed |
| EP-2665362-B1 | OLEFIN CONTAINING NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | KARYOPHARM THERAPEUTICS INC (US) | 2016-03-30 | — | — | EP | disclosed |
| EP-2665362-B1 | OLEFIN CONTAINING NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | KARYOPHARM THERAPEUTICS INC (US) | 2016-03-30 | — | — | EP | disclosed |
| US-20140155370-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | Karyopharm Therapeutics Inc. | 2014-06-05 | — | — | US | disclosed |
| EP-2665362-A1 | OLEFIN CONTAINING NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | Karyopharm Therapeutics, Inc. (US) | 2013-11-27 | — | — | EP | disclosed |
| CN-103402359-A | Olefin containing nuclear transport modulators and uses thereof | KARYOPHARM THERAPEUTICS INC | 2013-11-20 | — | — | CN | disclosed |
| US-8513230-B2 | Nuclear transport modulators and uses thereof | KARYOPHARM THERAPEUTICS, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-20120258986-A1 | OLEFIN CONTAINING NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | KARYOPHARM THERAPEUTICS, INC. (US) | 2012-10-11 | — | — | US | disclosed |
| US-20120258986-A1 | OLEFIN CONTAINING NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | KARYOPHARM THERAPEUTICS, INC. (US) | 2012-10-11 | — | — | US | disclosed |
| WO-2012099807-A1 | OLEFIN CONTAINING NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | KARYOPHARM THERAPEUTICS, INC. (US) | 2012-07-26 | — | — | WO | disclosed |
| WO-2012099807-A1 | OLEFIN CONTAINING NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | KARYOPHARM THERAPEUTICS, INC. (US) | 2012-07-26 | — | — | WO | disclosed |
| US-20110275607-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | KARYOPHARM THERAPEUTICS, INC. (US) | 2011-11-10 | — | — | US | disclosed |
| WO-2011109799-A1 | NUCLEAR TRANSPORT MODULATIORS AND USES THEREOF | KARYOPHARM THERAPEUTICS, INC. (US) | 2011-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140155370-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | XPO1, NXF1, XPOT | CES2 4629/4885GPBAR1 1077/4885MAPT 2798/4885 |
| US-20110275607-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | XPO1, NXF1, XPOT | CES2 4629/4885GPBAR1 1077/4885MAPT 2798/4885 |
| US-20120258986-A1 | OLEFIN CONTAINING NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | NXF1, NCOA1, XPO1 | CES2 4724/4885GPBAR1 529/4885MAPT 2553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.